glp 1 r retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Beyond GLP-1: Retatrutide's triple-agonist mechanism

Studies have also demonstrated changes in other inflammatory markers, including fibrinogen, plasminogen activator inhibitor-1 (PAI-1), and various adhesion molecules involved in vascular inflammation

While the core patent in India expires in March 2026, the US patent was granted a Patent Term Extension (PTE) that pushes exclusivity to December 2031

Allulose & GLP-1: Can a Sweetener Work to Help You Lose Weight

In a retrospective study of trends in prescribing AOM from 2004 to 2018, phentermine was the most widely prescribed weight loss medication (50% in 2018), followed by naltrexone-bupropion (19%) and liraglutide 3.0 mg (13%)